Blog

Creating a Patient- and Site-Centric Environment for Decentralized Clinical Trials

Hear from the Experts! 

As decentralized clinical trials reshape the clinical research landscape, Chief Innovation Officer Rob Laurens and Lead Concierge Alex Nicholl discuss efforts to help study sponsors embrace these trials with ease and confidence.

Earlier this week, BBK Principal Rob Laurens went one-on-one with Outsourcing-Pharma discussing the launch of BBK's Engagement Solution Center for decentralized and post-marketing clinical trials, which features concierge service delivery and a robust patient experience portal to ease the clinical trial journey.

In this in-depth interview, Rob addresses the importance and advantages of centralizing design, management, operations, and communications of patient support services. In addition, he provides insight into some of the conversations that led to the creation of the center. Click here to read the full article.

BBK Worldwide Launches the Engagement Solution Center for Decentralized and Post-Marketing Clinical Trial Success

Concierge Service Delivery and Robust Patient Experience Portal Ease Clinical Trial Journey

The COVID-19 pandemic has significantly accelerated the need to reshape research and development. Most specifically, it has led to demand for increased funding for decentralized and larger randomized clinical trials to inform clinical decisions and guide future research.

By launching the Engagement Solution Center, BBK Worldwide (BBK) is making patient-centric and inclusive trials an immediate and actionable reality for study sponsors.

For part two of our Crystal Ball series, we asked a few more of our industry experts to comment on the clinical research landscape and to share their predictions for 2021.

Rob Laurens, Principal, RSG Services

Do you think a lot of the travel services rapidly deployed in response to COVID-19 will remain in effect? Will they become part of the standard offering?

Undoubtedly, many of the extraordinary support services deployed as a means to directly respond to the impact of the COVID-19 pandemic on clinical trial participant travel not only will remain available after the distribution and anticipated positive impact of vaccines, but also will be enhanced to serve the needs of a redefined approach and capabilities for clinical trial conduct by sponsors and CROs. 

Earlier this week, Principal of RSG Services Rob Laurens went one-on-one with Outsourcing-Pharma to discuss challenges associated with patient travel as COVID-19 restrictions ease.

In this in-depth interview, Rob addresses the importance of contingency planning, lessons learned, and the long-term impact of COVID-19 on patient travel. He also provides insight into services and resources that clinical trial sponsors can leverage to maximize patient safety and engagement during COVID-19 and beyond. Click here to read the full article.

The Road to Reopening

In our newest Pharma15 Live! episode, Principal of RSG Services Rob Laurens provides guidance on managing clinical trial patient travel as COVID-19 restrictions ease and countries and study sites start to reopen.

Rob answers common questions and highlights the advantages of thoughtful pre-planning and contingency preparation. Watch now and discover strategies clinical trial sponsors can leverage to maximize patient safety and engagement during COVID-19 and beyond.

Download the eBook

Because there's a lot to consider in terms of managing patient travel as COVID-19 restrictions ease, we've captured guidance in a special eBook to download and review at your convenience.

Insights from Advarra on Managing Changes to Patient Enrollment & Engagement due to COVID-19

Get an IRB's perspective on managing clinical trial enrollment modifications due to COVID-19 by watching our interview with Michele Russell-Einhorn, Chief Compliance Officer and Institutional Official, Advarra.